Evidence-based review of the black-box warning for droperidol

American Journal of Health-System Pharmacy

Volumn 64, Issue 11, 2007, Pages 1174-1186

  Jackson, Cherry W ^a   Sheehan, Amy Heck ^b,c   Reddan, Jennifer G ^d  

^a AUBURN UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY HEALTH   (United States)

^d Clarian Health Partners   (United States)

Author keywords

Anxiolytics, sedatives and hypnotics; Dosage; Droperidol; Food and Drug Administration (U.S.); Labeling; Toxicity

Indexed keywords

AMFEBUTAMONE; AMLODIPINE; CHLORPROMAZINE; CLINDAMYCIN; CYCLOBENZAPRINE; DICLOFENAC; DROPERIDOL; FLUOXETINE; FUROSEMIDE; HALOPERIDOL; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LACTULOSE; LEVOMEPROMAZINE; OXAZEPAM; PIMOZIDE; SIMVASTATIN; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROMIDE; ZOLPIDEM; ZUCLOPENTHIXOL;

ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CHEMOPROPHYLAXIS; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE BIGEMINY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; TORSADE DES POINTES;

EID: 34249779557     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060505     Document Type: Article

References (31)

1. Henzi I, Sonderegger J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth. 2000; 47:537-51.
2. McEvoy GK, ed. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2005:2419-21.
3. Apfel CC, Korttila K, Abdalla M et al. A factorial trial of six interventions for the prevention of post-operative nausea and vomiting. N Engl J Med. 2004; 350:2441-51.
4. Andrews PL. Physiology of nausea and vomiting. Br J Anesth. 1992; 69(suppl 1):2S-19S.
5. Gan TJ. Post-operative nausea and vomiting - can it be eliminated? JAMA. 2002; 287:1233-6.
6. Fortney JT, Gan TJ, Graczyk S et al. A comparison of the efficacy, safety and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. Anesth Analg. 1998; 86:731-8.
7. Domino KB, Anderson EA, Polissar NL et al. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesth Analg. 1999; 88:1370-9.
8. Chen JJ, Frame DG, White TJ. Efficacy of ondansetron and prochlorperazine for the management of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. Arch Intern Med. 1998; 158:2124-8. [Erratum, Arch Intern Med. 1999; 159:615.]
9. Tang J, Watcha MF, White PF. A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures. Anesth Analg. 1996; 83:304-13.
10. Hill RP, Lubarsky DA, Phillips-Bute B et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol or placebo. Anesthesiology. 2000; 92:958-67.
11. Guy JM, Andre-Fouet X, Porte J et al. [Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol.] Ann Cardiol Angeiol. 1991; 40:541-5. In French.
12. Michalets EL, Smith LK, Van Tassel ED. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother. 1998; 32:61-5.
13. Bhatt SH. Cost impact of a prochlorperazine shortage on antiemetic prescribing in a community hospital. Presented at ASHP Midyear Clinical Meeting. Orlando, FL; 2004 Dec.
14. Glass PS. PONV: what is the role of the anesthesiologist? www.cucrash.com/Handouts04/PONVGlass.pdf (accessed 2007 Mar 28).
15. Gan TJ. A look at the recent droperidol warning. www.sambahq.org/ professional-info/newsletter/April2002.pdf (accessed 2007 Mar 28).
16. Young D. Black-box warning for droperidol surprises pharmacists. Am J Health-Syst Pharm. 2002; 59:494. News.
17. Prielipp RC, Baiser JR. FDA should reconsider droperidol warning. www.apsf.org/resource_center/newsletter/2002/spring/16letters_droperidol.htm (accessed 2007 Feb 12).
18. Horowitz BZ, Bizovi K, Moreno R. Droperidol: behind the black box warning. Acad Emerg Med. 2002; 9:615-8.
19. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
20. Food and Drug Administration. "Dear Health Care Professional" letter from Akorn Pharmaceuticals on December 4, 2001. www.fda.gov/medwatch/ SAFETY/2001/insapine (accessed 2007 Feb 12).
21. Lischke V, Behne M, Doelken P et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg. 1994; 79:983-6.
22. Reilly JG, Ayis SA, Ferrier IN et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000; 355:1048-52.
23. Charbit B, Albaladejo P, Funck-Brentano et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005; 102:1094-100.
24. Wolbrette DL Drugs that cause torsades de pointes and increase the risk of sudden cardiac death. Curr Cardiol Rep. 2004; 6:379-84.
25. Gowda RM, Khan IA, Wilbur SL et al. Torsade de pointes: the clinical considerations. Int J Cardiol. 2004; 96:1-6.
26. Liu BA, Juurlink DN. Drugs and the QT . interval - caveat doctor. N Engl J Med. 2004; 351:1053-6.
27. Al-Khatib SM, LaPointe NM,K ramer JM et al. What clinicians should know about the QT interval. JAMA. 2003; 289:2120-7. [Erratum, JAMA. 2003; 290:1318.]
28. Rewari V, Kaul H. Sustained ventricular tachycardia in long QT syndrome: is propofol the culprit? Anesthesiology. 2003; 99:764. Letter.
29. Sakabe M, Fujiki A, Inoue H. Propofol induced marked prolongation of QT interval in a patient with acute myocardial infarction. Anesthesiolgy. 2002; 97:265-6.
30. White PF, Song D, Abrao J et al. Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study. Anesthesiology. 2005; 102:1101-5.
31. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350:1013-22.